Nursing Clinical Insights Into the Benefits and Challenges of EGFR TKIs in the Treatment of NSCLC
This activity contains:
- CNE-Certified Virtual Grand Rounds
- Downloadable Slide Deck (a non-certified educational resource)
Release Date: 1/18/2017
Expiration Date: 1/17/2018
Estimated time to complete activity: 30 minutes
The goal of this activity is to provide nurses and other healthcare professionals the latest information on the use of EGFR TKIs in the treatment of NSCLC.
Lung cancer is the leading cause of cancer death. Approximately 85% of lung cancer cases are non–small cell lung cancer (NSCLC), 10% to 15% of which are epidermal growth factor receptor (EGFR) mutation positive. The development of EGFR inhibitors (eg, tyrosine kinase inhibitors [TKIs]) has led to targeted therapy, advancing the management of NSCLC. Unfortunately, the disease often develops resistance to some of these therapies; however, significant progress has been made in the treatment of NSCLC.
Recent advances in next-generation EGFR TKIs have shown promising results in patients with EGFR mutation–positive refractory NSCLC.
This activity provides learners with information regarding recent advances in the identification of predictive biomarkers and the EGFR TKI treatment paradigm, efficacy and safety information about approved and emerging TKIs used to treat EGFR mutation–positive NSCLC, and provides some insight into how healthcare clinicians can help educate patients and their caregivers about this topic.
This activity is intended for oncology nurses, thoracic nurses, pulmonary nurses, and other healthcare professionals who treat and manage non–small cell lung cancer.
Lori McMullen, MSN, RN, OCN®
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.50 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
Lori McMullen, MSN, RN, OCN®
Lori McMullen, MSN, RN, OCN® has no real or apparent conflicts of interest to report.
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS, Ronald Viggiani, MD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
There is no fee for this educational activity.
This activity is provided by:
- 0.50 ANCC
- 0.50 Attendance
At the conclusion of this activity, participants should be better able to:
- Discriminate among molecular characteristics or biomarkers that may be used to refine prognosis and/or predict response to an individual treatment in patients with non–small cell lung cancer
- Demonstrate an understanding of personalized medicine based on molecular subtype of EGFR mutation–positive non–small cell lung cancer
- Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors in non–small cell lung cancer
- Analyze data about the efficacy and safety of currently available and emerging EGFR tyrosine kinase inhibitors used to treat non–small cell lung cancer
- Identify best practices to facilitate oral therapy adherence among patients with non–small cell lung cancer
- Recognize appropriate strategies for the management of toxicities from treatment with available and emerging drugs in EGFR mutation–positive advanced non–small cell lung cancer